Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Pharmacol
Egile Nagusiak: Cecere, Sabrina C., Rossetti, Sabrina, Cavaliere, Carla, Della Pepa, Chiara, Di Napoli, Marilena, Crispo, Anna, Iovane, Gelsomina, Piscitelli, Raffaele, Sorrentino, Domenico, Ciliberto, Gennaro, Maiolino, Piera, Muto, Paolo, Perdonà, Sisto, Berretta, Massimiliano, Pignata, Sandro, Facchini, Gaetano, D'Aniello, Carmine
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2016
Gaiak:
Pharmacology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5005368/
https://ncbi.nlm.nih.gov/pubmed/27630568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00287
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak